Background: Hyperferritinemia, characterized by elevated serum ferritin levels, affects approximately 5–25% of the general population. Given the frequent coexistence of liver iron overload syndrome and metabolic syndrome—both of which significantly contribute to global morbidity and mortality—it is essential to investigate their interconnections. However, there is a lack of sufficient evidence, both in Mongolia and internationally, regarding the relationship between iron storage indicators, metabolic syndrome, and its components. A deeper understanding of iron’s role in disease progression is needed. Aim: This study aims to assess the association between hyperferritinemia and metabolic syndrome parameters. Materials and Methods: A cross-sectional analytical observational study was conducted on 159 male participants who met the inclusion criteria. Data were collected using a standardized questionnaire, and anthropometric measurements were taken. Blood samples were analyzed to determine glucose, triglyceride, total cholesterol, and high-density lipoprotein (HDL) levels using an automated biochemical analyzer. Serum ferritin concentrations were measured via the ELISA method (DRG Instruments GmbH, Germany), with hyperferritinemia defined as a serum ferritin level exceeding 400 ng/ ml. Metabolic syndrome was diagnosed based on the Harmonized criteria. Statistical analyses included the chi-square test and Fisher’s exact test for categorical variables, the Mann-Whitney U test for non-normally distributed data, and Spearman’s correlation test to assess relationships between glycemic levels, lipid parameters, and metabolic syndrome components. Results: The findings indicate that 59 participants (37.1%) had metabolic syndrome, while 33 (20.8%) presented with hyperferritinemia. The presence of metabolic syndrome and hyperglycemia increased the likelihood of developing hyperferritinemia by 3.4 and 3.7 times, respectively, whereas abdominal obesity raised the risk by 2.2 times. Conclusion There was a significant correlation between serum ferritin levels and certain parameters of metabolic syndrome among the male participants in this study.

Background: Iron deficiency (ID) and iron deficiency anemia (IDA) are among the most common forms of anemia worldwide. Although the underlying causes of ID may vary depending on a country’s developmental level, lifestyle, and other factors, blood loss remains the principal cause leading to ID and subsequent IDA. In hemophilia, recurrent bleeding due to deficiencies of coagulation factors (FVIII, FIX, FXI) can lead to ID, which may progress to IDA and adversely affect the quality of life in these patients. The absence of studies evaluating the prevalence of ID and IDA among hemophiliac patients in Mongolia provided the impetus for this investigation. Aim: To assess the prevalence of ID and IDA among patients with hemophilia. Materials and Methods: A cross-sectional study was conducted among 45 patients with hemophilia registered at the Hemophilia Comprehensive Center (HCC), Mongolia-Japan Hospital, Mongolian National University of Medical Sciences. All participants underwent laboratory testing, including complete blood count (CBC) and serum ferritin levels—were performed using the SYSMEX XN2000 and COBAS BM6010 analyzers. Data analysis was carried out using SPSS 27.0 and MS Excel 2010. Results: Among the 45 cases, 41 were Hemophilia A and 4 were Hemophilia B. Reduced serum iron levels were found in 33.3% (15), and low ferritin levels were observed in 22.2%. Detailed blood tests revealed microcytic hypochromic changes in 43.9% (18) of Hemophilia A cases and in 100% (4) of Hemophilia B cases. The overall prevalence of ID was 13.3%, while the prevalence of IDA was 22.2%. Among the IDA cases, 90.0% were classified as mild and 10.0% as moderate. Notably, 80.0% of the IDA cases occurred in children under 15 years of age. Conclusion ID and IDA are common among hemophiliac patients. The high prevalence among children under 15 years of age suggests an age-related predisposition, emphasizing the need to improve disease management and to implement preventive measures against anemia in this population.

Background: Hypokalemia is considered when the serum potassium level is less than 3.5 mmol/L. Clinical research indicates that hypokalemia affects 20% of hospitalized patients, and in 24% of these cases, inadequate interventions result in life-threatening complications. At present, there is no research available on the prevalence, management, and outcomes of hypokalemia in hospitalized patients, which justifies the need for this study. Aim: The study aimed to examine the prevalence of hypokalemia and the effectiveness of its management in hospitalized patients within the internal medicine department, in relation to the knowledge of doctors and resident physicians. Materials and Methods: This hospital-based retrospective study included a total of 553 cases of patients hospitalized in the Internal Medicine Department of the Mongolia Japan Hospital between January 2024 and August 2024. Patients with a potassium level of <3.5 mmol/L were diagnosed with hypokalemia, and the effectiveness of potassium replacement therapy was evaluated according to the method of supplementation employed. Results: The prevalence of hypokalemia among hospitalized patients in the Internal Medicine Department was 9.8% (54 cases). Based on the study criteria, 42 cases of hypokalemia were selected for further analysis, and a total of 118 potassium replacements were performed through oral, intravenous, and mixed methods. Following potassium replacement therapy, 37.3% (44) of patients achieved normalized potassium levels, while 62.7% (74) still had persistent hypokalemia. Conclusion According to the study results, the prevalence of hypokalemia among hospitalized patients in the Internal Medicine Department is 9.8%. The method of potassium replacement and the severity of hypokalemia do not impact the normalization of potassium levels, with the critical factor being the proper dosage of supplementation. The knowledge of doctors and resident physicians regarding hypokalemia is insufficient, and there is a need to implement guidelines and protocols for potassium replacement therapy in daily clinical practice.